Full-Time

Sr Electrical Project Engineer

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

No salary listed

Senior

Limerick, Ireland

Category
Control Systems Engineering
Electronics Design Engineering
Electrical Engineering
Requirements
  • BS/BEng or higher in Electrical Engineering
  • 5+ years of related experience
  • Direct experience with biopharmaceutical process equipment preferred
  • Excellent communication, negotiation, and stakeholder management skills
  • Ability to think strategically and execute tactically in a fast-paced environment
  • Ability to prioritize and adapt to change
Responsibilities
  • Designing and specifying electrical equipment and controls
  • Managing small-to-mid sized projects related to electrical equipment and infrastructure
  • Assisting in the design review, site acceptance and installation of electrical equipment
  • Preparing electrical diagrams and schematics
  • Supporting QA Validation department by preparation of design documents and assists in protocol execution
  • Assisting in investigations of process equipment, utility systems, and control system anomalies, as well as safety incidents
  • Implementing corrective/preventative actions for existing equipment and electrical processes
  • Preparing engineering evaluations and test plans for and executes change control documentation
  • Maintaining a clean and safe working environment by enforcing procedures, policies, and regulations
  • Maintaining company reputation by enforcing compliance with all relevant laws, policies and regulations
  • Providing supervision to electrical contractors, may be required
Desired Qualifications
  • Direct experience with biopharmaceutical process equipment preferred
  • May substitute relevant experience for education
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and strategic partnerships. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's $3.6 billion Tarrytown expansion boosts research and manufacturing capabilities.
  • Dupixent's approval for chronic spontaneous urticaria opens new market opportunities.
  • Regeneron's investment in biologics manufacturing aligns with rising demand trends.

What critics are saying

  • Heavy reliance on Eylea and Dupixent makes Regeneron vulnerable to market changes.
  • Increased competition from biosimilars could erode Regeneron's market share.
  • Tarrytown facility expansion poses financial risks if ROI expectations aren't met.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery and development.
  • Strategic collaborations enhance Regeneron's research and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PR Newswire
May 16th, 2025
75Th Annual Regeneron International Science And Engineering Fair Awards Teen Scientists From Around The World More Than $9 Million In 2025 Competition

Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, OhioTARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named in honor of pioneering drug developer and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer. Other top prizes went to projects in sustainable plastics engineering, air quality detection and advancement in prosthetics.Congratulations to the winners of the 2025 Regeneron International Science and Fair!The top winners were recognized during two award ceremonies: the Special Awards on May 15 and the Grand Awards Ceremony on May 16

Ophthalmology Times
Apr 28th, 2025
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.